Aktienanalyse zu Akebia Therapeutics Inc (AKBA)AKBAAkebia Therapeutics Inc

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Akebia Therapeutics Inc is not a good buy right now due to its current price of $0.67, which is significantly below the analyst price target of $4.50 from WestPark Capital. Additionally, the stock has a very low RSI of 10.385, indicating it is oversold, but the overall trend shows a 78.80% decline over the past year, raising concerns about its long-term viability. The main risk is the negative sentiment reflected in the recent earnings report, where revenue declined by 21.6% year-over-year, despite a slight earnings beat.

7 analysts cover AKBA: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 5.00.